StageZero Life Sciences Ltd. – TSX:SZLS.TO
StageZero Life Sciences Ltd. stock price today
StageZero Life Sciences Ltd. stock price monthly change
StageZero Life Sciences Ltd. stock price quarterly change
StageZero Life Sciences Ltd. stock price yearly change
StageZero Life Sciences Ltd. key metrics
Market Cap | 1.85M |
Enterprise value | 10.84M |
P/E | -0.6 |
EV/Sales | 2.34 |
EV/EBITDA | -3.11 |
Price/Sales | 1.97 |
Price/Book | 6.32 |
PEG ratio | -0.01 |
EPS | -0.03 |
Revenue | 2.83M |
EBITDA | -3.10M |
Income | -3.80M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -91.17% |
Oper. margin | -197.09% |
Gross margin | -0.56% |
EBIT margin | -197.09% |
EBITDA margin | -109.31% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeStageZero Life Sciences Ltd. stock price history
StageZero Life Sciences Ltd. stock forecast
StageZero Life Sciences Ltd. financial statements
| Mar 2023 | 778.51K | -2.19M | -282.13% |
|---|---|---|---|
| Jun 2023 | 793.30K | -401.53K | -50.62% |
| Sep 2023 | 745.48K | -821.88K | -110.25% |
| Mar 2024 | 521.92K | -386.34K | -74.02% |
| Mar 2023 | 683863 | 9.66M | 1412.62% |
|---|---|---|---|
| Jun 2023 | 784492 | 9.19M | 1172.48% |
| Sep 2023 | 508422 | 9.58M | 1884.85% |
| Mar 2024 | 379466 | 10.57M | 2788% |
| Mar 2023 | -223.23K | 0 | 243.85K |
|---|---|---|---|
| Jun 2023 | 7.05K | 0 | 20.85K |
| Sep 2023 | 47.81K | 0 | -87.93K |
| Mar 2024 | -92.93K | 0 | 72.08K |
StageZero Life Sciences Ltd. alternative data
| Aug 2023 | 40 |
|---|---|
| Sep 2023 | 40 |
| Oct 2023 | 40 |
| Nov 2023 | 40 |
| Dec 2023 | 40 |
| Jan 2024 | 40 |
| Feb 2024 | 40 |
| Mar 2024 | 40 |
| Apr 2024 | 40 |
| May 2024 | 40 |
| Jun 2024 | 40 |
| Jul 2024 | 40 |
StageZero Life Sciences Ltd. other data
-
What's the price of StageZero Life Sciences Ltd. stock today?
One share of StageZero Life Sciences Ltd. stock can currently be purchased for approximately $0.3.
-
When is StageZero Life Sciences Ltd.'s next earnings date?
Unfortunately, StageZero Life Sciences Ltd.'s (SZLS.TO) next earnings date is currently unknown.
-
Does StageZero Life Sciences Ltd. pay dividends?
No, StageZero Life Sciences Ltd. does not pay dividends.
-
How much money does StageZero Life Sciences Ltd. make?
StageZero Life Sciences Ltd. has a market capitalization of 1.85M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 25.12% to 3.8M US dollars.
-
What is StageZero Life Sciences Ltd.'s stock symbol?
StageZero Life Sciences Ltd. is traded on the TSX under the ticker symbol "SZLS.TO".
-
What is StageZero Life Sciences Ltd.'s primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of StageZero Life Sciences Ltd.?
Shares of StageZero Life Sciences Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does StageZero Life Sciences Ltd. have?
As Jul 2024, StageZero Life Sciences Ltd. employs 40 workers.
-
When StageZero Life Sciences Ltd. went public?
StageZero Life Sciences Ltd. is publicly traded company for more then 21 years since IPO on 7 Jan 2004.
-
What is StageZero Life Sciences Ltd.'s official website?
The official website for StageZero Life Sciences Ltd. is stagezerolifesciences.com.
-
Where are StageZero Life Sciences Ltd.'s headquarters?
StageZero Life Sciences Ltd. is headquartered at 70 East Beaver Creek Road, Richmond Hill, ON.
-
How can i contact StageZero Life Sciences Ltd.?
StageZero Life Sciences Ltd.'s mailing address is 70 East Beaver Creek Road, Richmond Hill, ON and company can be reached via phone at +90 52092030.
StageZero Life Sciences Ltd. company profile:
StageZero Life Sciences Ltd.
stagezerolifesciences.comTSX
40
Medical - Diagnostics & Research
Healthcare
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
Richmond Hill, ON L4B 3B2
:
ISIN: CA8525403017
:
